TPST-4003, Tempest Therapeutics’ next-generation CAR T-cell therapy for autoimmune diseases such as myasthenia gravis (MG), will soon be tested in people for the first time, the developer announced. The upcoming investigator-initiated clinical trial, to be conducted in China by Senlang Biotechnology, will assess the effects of this new…
News
Repeated cycles of Rystiggo (rozanolixizumab-noli) were generally well tolerated and consistently eased symptoms over a median study duration of about two years among people with generalized myasthenia gravis (gMG). That’s according to a final analysis of pooled data from the global Phase 3 MycarinG clinical trial (NCT03971422) and…
Thymectomy, or the surgical removal of the thymus gland, may help people with myasthenia gravis (MG) achieve and maintain disease remission without the need for other treatments, according to a study in China. Thymectomy was significantly associated with a threefold higher chance of achieving that outcome, called maintained…
Financial strain and disruptions in planning and independence were among the most relevant burdens reported by people living with generalized myasthenia gravis (gMG) and their caregivers, according to a U.S. study. The reported burden tended to be greater among patients with more severe disease and among caregivers who were…
Diabetes, a condition marked by chronically high blood sugar (glucose) levels, may worsen symptoms in people with myasthenia gravis (MG) by promoting the activation of B-cells, the immune cells that produce the disease-causing antibodies, a study suggests. The researchers found that harmful compounds that accumulate when excess sugar molecules bind…
Dianthus Therapeutics has launched a global, late-stage clinical trial to evaluate the safety and effectiveness of its self-administered injection therapy claseprubart versus a placebo in people with generalized myasthenia gravis (gMG). The Phase 3 study, dubbed EMERGE (NCT07647510), is expected to enroll an estimated 195 adults with…
To successfully navigate life with myasthenia gravis (MG), people need to be aware of their own bodies and limitations, make proactive plans to set themselves up for success — and, above all, ask for help when it’s needed. “Living with myasthenia gravis independently doesn’t necessarily mean we’re doing everything…
Use of the approved therapy Imaavy (nipocalimab-aahu) leads to a lasting drop in symptoms and related gains in quality of life for adults with generalized myasthenia gravis (gMG) treated early in their disease course, with significant benefits also seen among patients with less severe symptoms at diagnosis. Further,…
Antibodies against the muscle-specific kinase (MuSK) protein may help identify a generally more severe form of myasthenia gravis (MG), one often marked by problems with speech and swallowing and a need for more intensive treatment, a study found. This form of MG varied unexpectedly in frequency among seronegative MG…
UCB’s Rystiggo (rozanolixizumab-noli) and Zilbrysq (zilucoplan) have gained public reimbursement coverage across multiple Canadian provinces for adults with generalized myasthenia gravis (gMG). Product listing agreements are now in place in British Columbia, Québec, Alberta, Saskatchewan, Nova Scotia, and Newfoundland and Labrador for both therapies, and in Ontario…
Recent Posts
- Human trial to start this year for next-generation CAR T-cell therapy for MG
- Being a caregiver with MG means keeping my distance
- Guest Voice: Taking back control of my life from myasthenia gravis
- How people respond to my MG, and what I wish they’d do instead
- Repeated treatment cycles ease gMG symptoms across long-term study